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A microfluidic platform for the characterisation of
membrane active antimicrobials†
K. Al Nahas, a J. Cama, a M. Schaich, a K. Hammond,b S. Deshpande, c
C. Dekker, c M. G. Ryadnov b and U. F. Keyser *a
The spread of bacterial resistance against conventional antibiotics generates a great need for the discovery
of novel antimicrobials. Polypeptide antibiotics constitute a promising class of antimicrobial agents that fa-
vour attack on bacterial membranes. However, efficient measurement platforms for evaluating their mech-
anisms of action in a systematic manner are lacking. Here we report an integrated lab-on-a-chip multilayer
microfluidic platform to quantify the membranolytic efficacy of such antibiotics. The platform is a biomi-
metic vesicle-based screening assay, which generates giant unilamellar vesicles (GUVs) in physiologically
relevant buffers on demand. Hundreds of these GUVs are individually immobilised downstream in physical
traps connected to separate perfusion inlets that facilitate controlled antibiotic delivery. Antibiotic efficacy
is expressed as a function of the time needed for an encapsulated dye to leak out of the GUVs as a result
of antibiotic treatment. This proof-of-principle study probes the dose response of an archetypal polypep-
tide antibiotic cecropin B on GUVs mimicking bacterial membranes. The results of the study provide a
foundation for engineering quantitative, high-throughput microfluidics devices for screening antibiotics.
1 Introduction
Phospholipid membranes provide bacterial cells with a per-
meability barrier that prevents conventional antibiotics from
reaching their intracellular targets. This role of the mem-
branes is particularly important for developing antibiotics
targeting Gram-negative bacteria, whose two (outer and inner)
membranes present a formidable challenge for any antibiotic
to overcome.1,2 This is one major reason behind the failure of
traditional target-oriented in vitro screening assays in the
pharmaceutical industry, which repeatedly failed to discover
novel agents active against Gram-negative bacteria simply be-
cause the candidate drugs failed to accumulate at sufficient,
inhibitory concentrations in the vicinity of their targets.
Therefore, there is a strong drive towards the discovery of
antibiotics that target bacterial membranes.
To counteract microbial invasions, multicellular organ-
isms rely on innate host defence mechanisms which make
use of host defence peptides.3 These are effector molecules of
innate immunity that have an intrinsic ability to recognise,
bind to and disrupt microbial phospholipid membranes.
This inspires continuous searches for novel peptides and at-
tempts to design and redesign de novo engineered peptides
into more effective antimicrobial agents. Naturally occurring,
synthetic and designed antimicrobial peptides (AMPs) have
evolved into one of the most promising classes of antimicro-
bial agents that can be converted into a sustainable pipeline
of next generation antibiotics.4
However, an efficient pipeline requires effective tools to
measure antimicrobial efficacy in a systematic manner ulti-
mately opening up new possibilities for high-throughput
screening platforms. Antimicrobial activity is typically mea-
sured by microdilution assays that provide the minimum in-
hibitory concentration (MIC) of a given antibiotic. The accu-
racy of such assays is subject to the inoculum effect,5 as the
efficacy of AMPs may vary due to their stochastic binding to
bacteria causing fluctuations in peptide concentration. Im-
aging techniques can reveal useful mechanistic information
of the targeted activity at a single membrane level, which
bulk culture assays, such as MIC assays, cannot capture. In
this regard, highly controlled in vitro optical methods may
provide drug developers with a highly efficient and reliable
procedure for probing the antimicrobial activity of emerging
antibiotics.
Most AMPs are cationic and favour interactions with an-
ionic bacterial membranes. These interactions can be corre-
lated with the phospholipid composition of the membranes
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allowing them to be reconstituted in empirically predictable
model membranes.6 We leveraged this property of AMPs to de-
velop a microfluidic assay, which quantifies the membranolytic
activity of the peptides on thousands of individual, precisely
defined model membranes. Membranes in the format of giant
unilamellar vesicles (GUVs) are routinely used in research and
drug screening including studies on drug permeation and
transport through membrane pores,7–10 lipid scrambling11 and
membrane fluctuation.12 The size of GUVs is compatible with
the resolution of standard optical microscopy techniques
which, in conjunction with microfluidic tools that can reliably
form GUVs on chip,13–16 provide an attractive system for
membranolytic screening. For our platform, we adapted the
octanol-assisted liposome assembly (OLA) method as it has sev-
eral advantages when compared to other on-chip possibilities.
The technique yields homogeneous-size GUVs in a single step
process coupled with a short vesicle maturation period (∼mi-
nutes), and enables the high-throughput production of
vesicles.15
In order to optimise the output of a single experiment and
minimise the consumption of valuable peptides required for
characterisation, we developed a complete lab-on-a-chip plat-
form that integrates the OLA vesicle formation component
with a parallelised vesicle capture and drug perfusion system
(Fig. 1). The device enables the preparation of GUVs with de-
fined lipid compositions in abundant amounts with a rate of
tens of Hz and at physiological salt concentrations.15 Thou-
sands of GUVs can be immobilised downstream for long term
studies. The trap chambers are connected to perfusion inlets,
and the vesicles can be exposed to numerous different solu-
tions in parallel (Fig. 1). The ability to investigate populations
containing thousands of GUVs at the single-vesicle level is a
considerable improvement on earlier techniques where stud-
ies were conducted on tens of GUVs per experiment in open
chambers. Such throughput allows the acquisition of statisti-
cally significant results that portray the stochastic nature of
lipid–peptide interactions.
We validate our platform for the characterisation of mem-
brane active polypeptides by conducting a dose response
study using cecropin B, a representative native AMP that is
known to lyse Gram-negative bacterial cell membranes.17
Using our platform, we quantified the membranolytic activity
of the peptide using a fluorescence-based readout that corre-
lates peptide activity with the leakage of an encapsulated
membrane-impermeable dye from the GUV. The validation is
aimed at qualifying our approach as an AMP characterisation
assay in the pre-clinical development of membrane active
antibiotics.
2 Experimental
2.1 Microfluidic chip design
Our microfluidic platform incorporates an on-chip giant vesi-
cle formation component.19 The octanol-assisted liposome as-
sembly technique enables the production of double-emulsion
droplets in a single step that result in giant unilamellar
Fig. 1 Overview of the microfluidic platform for testing the efficacy of membrane-active drugs on individual lipid vesicles. Schematic depiction of
a complete lab-on-a-chip platform for vesicle formation, trapping, and drug testing. The platform consists of a vesicle formation component and
8 separate chambers each encompassing an array of 372 vesicle traps. Vesicle transport to the trap chambers is facilitated via a second layer of
microfluidic channels, labelled as the connector chip (shown in red). The connector chip is a secondary PDMS layer that forms the only connection
between the vesicle formation channels and the trap reservoirs. This is achieved by aligning the connector chip vertically above the punched flu-
idic outlet of the vesicle formation component and the 8 punched inlets of the trap reservoirs (ESI† Fig. S1). A) Microscopic fluorescence images of
GUV formation using the octanol-assisted liposome assembly (OLA) technique. Vesicle formation is visualized with the fluorescent lipid Liss Rhod
PE (560 nm/583 nm) labelling the lipid phase (top), and the encapsulation of the membrane impermeable HPTS dye (454 nm/520 nm) labelling the
vesicle's interior (bottom). B) Schematic of vesicle trapping using an array of PDMS microposts as vesicle traps, and a corresponding microscopic
fluorescence image of trapped GUVs encapsulating the HPTS dye. Scale bars represent 50 μm.
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vesicles (Fig. 1A). The double emulsion droplets develop a
pocket accumulating excess 1-octanol and lipids, which buds
off on the timescale of minutes.19 We increased the size of the
vesicles (typical size range 20–28 μm in diameter) and the volu-
metric flow rate by doubling the height and width of the six-
way PDMS junction (design in the ESI† Fig. S1). The larger size
of the GUVs aided their visualization and trapping, while the
higher flow velocity optimised vesicle trapping, both in terms
of speed and efficiency.
The vesicle immobilisation component of the platform
contains 8 separate chambers of vesicle trap arrays inspired
by a published trap design.20 The features of the trapping re-
gion were tuned to achieve efficient capture for vesicles with
a diameter size of 20–25 μm. The gap size between the micro-
posts of a single trap was designed to be 20–25% of the vesi-
cles' diameter (design in the ESI† Fig. S2). Each trap array
consists of 372 vesicle traps in a single chamber (Fig. 1B). All
trap chambers are connected to perfusion inlets that are
utilised for peptide delivery. The vesicle trap system enables
us to conduct long duration studies of peptide–membrane in-
teractions; our experiments typically lasted up to 10 hours
post vesicle trapping.
The vesicle formation and capture components were inte-
grated in a single device to perform the processes of vesicle
formation and trapping sequentially and efficiently. To facili-
tate this, we designed a multi-layer device with a connector
layer on top of the main layer, incorporating a 1 mm wide
microfluidic channel. This optimises the transport and distri-
bution of the vesicles into the trap arrays (Fig. 1). The con-
nector chip offers four distinct advantages:
1. It provides a miniaturised logistical solution for the
handling of giant vesicles formed in the device, as it circum-
vents the task of extracting the vesicles off-chip and re-
introducing them into a second device for analysis.
2. It functions as a route for discharging vesicle produc-
tion waste, and in the present design is used to remove ex-
cess 1-octanol from the solutions prior to vesicle
immobilisation in the trap chambers.
3. It decouples the input pressures required for vesicle for-
mation from the fluidics of vesicle trapping and drug perfu-
sion. This is an important consideration, since vesicle forma-
tion is sensitive to small changes in input pressures.
4. It simplifies the surface treatment required for OLA ves-
icle formation.15 Before the assembly of the connector chip
to the device, the vesicle formation and trapping components
of the main bottom layer (Fig. 1) are separated. Thus only the
vesicle formation part of the chip can be coated, with the trap
chambers and perfusion system completely unaffected during
the coating procedure. This precaution is important as the
vesicle traps are rendered dysfunctional, if the material used
for coating solidifies between the trapping micro-posts.18
2.2 Fabrication of the microfluidic chip
We fabricated a 3D microfluidic network in a multilayer poly-
dimethylsiloxane (PDMS) device using standard photo- and
soft-lithography techniques.21 Two master molds were fabri-
cated for the bottom (main) and upper (connector) micro-
fluidic layers (Fig. 1). The main channels were molded from
a master with two distinct feature heights of ∼20 μm and
∼30 μm. The master mold of the connector channel had fea-
tures of ∼40 μm in height. Silicon masters with feature
heights around 20, 30 and 40 μm were generated by spin-
coating (WS-650-23NPP, Laurell Technologies, USA) SU-8 2025
photoresist (Chestech, UK) at 3800, 2800, and 1800 rpm re-
spectively for 60 s with a ramp of 100 rpm s−1 on 4″ silicon
wafers (University Wafer, USA). The spin coating was followed
by a soft bake on a hot plate for 1 min at 65 °C followed by
5–6 min at 95 °C. A high-resolution, table-top laser direct im-
aging (LDI) system (LPKF ProtoLaser LDI, Germany) was used
for prototyping on the resist-coated substrates directly using
AutoCAD designs. In order to achieve different feature
heights on the same silicon wafer, the photolithography pro-
cess had to be performed twice on the same silicon wafer
using an anchoring tool for aligning the features in the two
designs. The printed master mold was then baked for 1 min
at 65 °C followed by 5 min at 95 °C, developed in propylene
glycol monomethyl ether acetate (PGMEA) for 2–3 min and
hard-baked for 15 min at 125 °C.
A PDMS replica embedding the molded structures was
obtained by mixing a siloxane elastomer with siloxane cross-
linker known as the curing agent (Sylgard 184, Dow Corning)
in a 9 : 1 ratio. The PDMS mixture was then degassed for 30
min in a desiccator, poured onto the SU-8 molds and baked
in the oven for 90 min at 60 °C. After curing and peeling off
the PDMS layers, inlets, outlets and connecting channels
were punched with a 750 μm biopsy punch (WPI, UK)
through the PDMS layers. The only exception was the outlet
of the bottom main layer (outlet A), which was punched with
a 1.5 mm biopsy punch. In order to accommodate the size of
the microfluidic platform, glass slides with dimensions of 76
mm × 39 mm and 1 mm thickness were coated with PDMS
and used as the base for the devices. The PDMS-coated glass
slides were prepared by following a previous protocol.15 The
main PDMS chips were bonded to the PDMS-coated glass
slides by exposing the surfaces to an oxygen plasma (100 W
plasma power, 10 s exposure, 25 sccm, plasma etcher from
Diener Electric GmbH & Co. KG) and then annealing the two
exposed surfaces together.
The surface of the microfluidic channels delivering the
outer aqueous solution (OA) was treated for 15 min with poly-
vinyl alcohol (PVA) solution (50 mg mL−1, 87–90% hydro-
lysed, molecular weight 30 000–70 000 Da, Sigma-Aldrich).19
Post treatment, the PVA is removed via vacuum pump suction
(Gardner Denver Thomas GmbH, Germany). A similar surface
treatment was performed for the connector channel by manu-
ally painting the open channels with 10 μL of PVA (10 mg
mL−1) using a pipette tip. The PVA-coated chips were then
baked at 120 °C for 15 min. Finally, the connector PDMS
layer was bonded on top of the main PDMS layer using a sim-
ilar plasma treatment, while aligning the connector channel
over the connecting holes (ESI† Fig. S3).
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2.3 Vesicle formation
The OLA technique allows considerable variety in the content
of the inner and outer aqueous phases (IA and OA). The base
stock used for the IA and OA phases consisted of a 200 mM
sucrose solution with 15% v/v glycerol in PBS for obtaining
pH 7.4 and a physiological salt concentration. The OA addi-
tionally contained 50 mg mL−1 of Kolliphor P-188 (Sigma-Al-
drich, UK), a poloxamer.15
Lipids were purchased from Sigma Aldrich in powder form
and were dissolved in 100% ethanol to a final concentration
of 100 mg mL−1. The lipid/octanol phase (LO) was prepared
by diluting the lipid stock in 1-octanol to a 2–4 mg mL−1 con-
centration. A lipid mixture of 3 : 1 ratio 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC) with 1,2-dioleoyl-sn-glycero-3-
phospho-rac-(1-glycerol) sodium salt (DOPG) was used to
mimic the bacterial membrane composition. In order to visu-
alize the LO phase, a fluorescently labelled lipid (16 : 0 Liss
Rhod PE, Avanti Lipids, 0.5 mg mL−1 in ethanol) was added to
the LO phase. The pH sensitive dye HPTS, (8-hydroxypyrene-
1,3,6-trisulfonic acid, Thermo Fisher), was used to stain the in-
ner aqueous phase at a concentration of 50 μm. HPTS dye was
chosen for this assay since it is a membrane impermeable
molecule with high stability against photo-bleaching.22
The vesicle formation component was controlled with a
pressure driven pump. We used a microfluidic flow control
system MFCS-EZ (Fluigent GmbH, Germany) and its accom-
panying MAESFLOW software (version 3.2.1) to control the
flow of the three different phases. The fluid reservoirs
(Micrewtube 0.5 mL, Simport) were connected to the micro-
fluidic chip via a polymer tubing (Tygon microbore tubing,
0.020″ × 0.060″ OD, Cole Parmer, UK) and a metal connector
tip. Cut syringe needles (Gauge 23, BD Microbalance) or dis-
pensing tips (Gauge 23 blunt end, Intertronics) served as con-
nector tips between the tubing and the chip.
2.4 Cecropin B synthesis and dose preparation
Cecropin B (KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL-
NH2) was assembled on a Liberty blue microwave peptide
synthesiser (CEM) using standard Fmoc/tBu solid-phase pro-
tocols with HBTU/DiPEA as coupling reagents on a Rink Am-
ide MBHA resin (0.35 mmol substitution; 100 μmol scale). Af-
ter post-synthesis cleavage and deprotection (95% TFA, 2.5%
TIS, 2.5% water), the peptide was purified by semi-
preparative reversed-phase high performance liquid chroma-
tography (RP-HPLC). The identity of the peptide was con-
firmed by analytical RP-HPLC and MALDI-ToF. Analytical and
semi-preparative RP-HPLC was performed on a Thermo Sci-
entific™ Dionex™ HPLC system (Ultimate 3000), using
Vydac C18 analytical and semi-preparative (both 5 μm) col-
umns. Both analytical and semi-preparative runs used a 10–
70% B gradient over 30 min at 1 mL min−1 and 4.5 mL min−1
respectively, with detection at 280 and 214 nm (buffer A, 5%
and buffer B, 95% aqueous CH3CN, 0.1% TFA). Cecropin B
was then lyophilised and stored in powder form at −80 °C.
Small amounts of the lyophilised peptide to be tested were
hydrated in Milli-Q water and used within two days of disso-
lution. The stock concentration was then measured using a
NanoDrop™ system and diluted to 100 μM dilution in the IA
buffer. The aliquot was then further diluted to the peptide
concentrations required for the experiment. The perfusion of
2.5 or 5 μM of cecropin B solution into the microfluidic de-
vice required a minimal amount of 1–3 μg of the peptide in
powder form. For visualization of drug arrival into the test
chambers, we diluted the HPTS dye (5 μM) into the peptide
solution. The peptide solutions were then stored at 4 °C
while the stock was stored at −20 °C.
2.5 Device operation
After device fabrication and assembly, the chip was placed in
a custom device holder (ESI† Fig. S3) that slots into a motor-
driven automated Prior XYZ-stage attached to an Olympus
IX73 inverted microscope. The fluids in the chip were con-
trolled using 7 pressure ports and a single syringe pump mod-
ule. Before connecting all the fluid reservoirs into the device,
a critical step involves filling the trapping component with IA
base stock to avoid air bubbles. This was done by connecting
a neMESYS syringe pump module to outlet A (Fig. 1). The sy-
ringe was used to flow IA buffer at 50 μL h−1 through the trap
chambers and push the air out of the connecting channels.
Once this is complete, the flow rate was reduced to 3–5 μL
h−1. The vesicle formation and perfusion inlets were then
connected to the pressure pump reservoirs and positive fluid
flows applied until an air-free device was obtained. At this
stage, the reservoirs of the perfusion inlets were loaded with
IA base stock. The outlet of the connector chip (outlet B) was
then connected to a 2-SWITCH™ (Fluigent) that can switch
between an open or closed configuration.
After formation, vesicles flow through a punched column
to the connector chip (Fig. 2). During this stage, the 1-octanol
pocket attached to a vesicle pinches off to form a 1-octanol
droplet as a byproduct. The connector chip contains an outlet
(outlet B in Fig. 1) that removes the vesicle production waste
from the device based on density separation.18 The connector
channel passes over the inlets of the connecting columns in
order to distribute the vesicles into the trapping chambers.
The trap chambers themselves are all connected to outlet A
(Fig. 1). Trapping is achieved by applying suction at outlet A
using the neMESYS syringe pump module. Fig. 2 schemati-
cally illustrates how the vesicles travel within the device.
Once a majority of the vesicle traps have been filled, the suc-
tion tube is removed leaving outlet A open and the chambers
are washed for an hour with IA buffer pumped from the per-
fusion inlets. The peptide dose was administered by filling
the peptide-dye solutions into new reservoirs, replacing the
initial reservoirs filled with IA buffer. The input pressure was
maintained at ∼20 mbar throughout the measurements.
2.6 Data acquisition and image processing
The automated stage is synchronised with a Photometrics
Evolve 512 camera via μManager 1.4 software with a wLS LED
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lamp from QImaging as the light source.23 A FITC filter cube
set (Chroma) was used for tracking HPTS fluorescence. The
automated stage enables the sequential acquisition of images
from all the trapping chambers. The size of a single trapping
chamber was designed to span 4 different fields of view when
using a 10× air objective (Olympus UPLFLN). An acquisition
cycle contains 32 selected positions that cover the 8 cham-
bers, with a 30 second window between the first frame of ev-
ery cycle. The acquisition was run over 2000 cycles, with the
time-lapse images stored in TIFF format. During analysis, the
trapped vesicles were manually selected using a custom plug-
in of the software FIJI and the fluorescence intensities of the
vesicles were measured.24 The acquired fluorescence signal
trace for every vesicle was initially smoothed using a
Savitzky–Golay filter in Origin. The signal was locally
normalised to the highest initial intensity of the fluorescent
vesicle coupled with global background subtraction using the
signal after peptide-dye arrival. The single vesicle resolution
data was sorted depending on the chamber that the vesicles
were trapped in, which corresponded to the concentration of
polypeptide tested. Since two trapping chambers were
connected to a single perfusion inlet, four independent ex-
periments could be run in parallel using one chip.
3 Results and discussion
In order to verify the assay, we monitored the vesicles' re-
sponse towards different doses of the antimicrobial peptide
cecropin B. At micromolar concentrations, the peptide has
been observed to form pores in membranes leading to cell
leakage.25,26 However, it has also been demonstrated that
pores formed by AMPs are not limited to a particular diame-
ter and can expand to the micron scale leading to the com-
plete disintegration of the membrane.27
Fig. 2 Side-view schematic illustrating vesicle transport through the multi-layer microfluidic device. The giant vesicles produced at the formation
junction are accompanied by a 1-octanol pocket. The pocket buds off and forms a 1-octanol droplet that coexists with the vesicles. As they leave
the formation channel, the 1-octanol droplets (ρ = 0.827 g mL−1) drift upwards and are separated.18 The vesicles are drawn into the vesicle trap ar-
rays by applying suction at outlet A (Fig. 1). The height of the formation junction and post-formation channel is 20 μm. The vesicles are usually
confined and in contact with the top and bottom walls of the channels until they arrive at the post-formation punched reservoir. In order to
reintroduce the vesicles into microfluidic channels with minimum shearing, the heights of the channels after formation were designed to be larger
than 20 μm:40 μm for the connector chip and 30 μm for the trap region to avoid immobilising overlapping vesicles.
Fig. 3 Representative sample of the data used to quantify the
membranolytic activity of cecropin B. Fluorescence microscopy images
of trapped GUVs (DOPC/DOPG lipids mixed at a 3 : 1 ratio). The trapped
vesicles encapsulate the membrane impermeable dye HPTS (50 μM).
The collage is a subset of images taken every hour displaying the time-
dependent membranolytic effect of 5 μM cecropin B on the membrane
integrity of the vesicles. The dark blue background marks the arrival of
the peptide to the chamber. The averaged normalised fluorescence de-
crease in intensity from the 14 trapped vesicles is mapped. The means
and standard error bars correspond to the fluorescence intensity of all
the vesicles in the aligned frames in the collage. Scale bar represents
50 μm. The corresponding video is in the ESI† SV1.
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The effect of the AMP was observed by continuously expos-
ing the trapped vesicles to 0, 2.5 and 5 μM of cecropin B in
separate chambers. The concentrations were chosen similar
to reported cecropin B MIC values against Gram-negative bac-
teria with MICs ranging between 0.15 and 4.2 μM.28,29 The vi-
ability of the trapped GUVs was monitored by recording the
intensity of the HPTS dye, encapsulated in the vesicle inte-
rior, sequentially over 10 hours. The membrane disrupting
activity of the polypeptides was quantified by correlating the
fluorescent dye leakage to the integrity of the vesicle's lipid
membrane. The time-point defining a compromised vesicle
was set as the point when the fluorescence signal intensity
decreased below 50% of its initial intensity.
Fig. 3 depicts how a representative group of trapped vesi-
cles in one chamber behaves after exposure to 5 μM of
cecropin B. Peptide arrival is displayed as a faint dark blue
background colour, corresponding to the fluorescence of the
diluted HPTS dye (5 μM) co-administered with the peptide so-
lutions. The vesicle collage contains 8 subsets of vesicles at
the same position with 1 hour in between each frame. The
normalised intensity traces of the 14 trapped vesicles were av-
eraged and plotted while displaying the standard error at the
time points referencing the corresponding frames. Fig. 3 also
shows some polydispersity in the trapped vesicles. This is typ-
ically caused either by small changes in the pressures applied
to the lipid and aqueous phases during the vesicle formation
process19 or by vesicle collisions with physical barriers.30
However, since our fluorescence measurement is relative to
the initial intensity at the individual vesicle level, the polydis-
persity has no significant effect on the outcome of our assay.
Fig. 4 represents the results from a single experiment ex-
amining the population of vesicles at the single-vesicle level
after treatment with cecropin B at 2.5 and 5 μM, in addition
to a control sample without exposure to the polypeptide
agent. In Fig. 4A–C every horizontal line depicts the
normalised intensity of the encapsulated HPTS in a single
vesicle. Red colour corresponds to the intensity of the encap-
sulated HPTS labelling intact vesicles, while the blue colour
represents the reduced signal associated with the vesicle be-
ing compromised, due to dye leakage. The white colour
Fig. 4 Cecropin B compromises model bacterial membranes in a dose-dependent manner. A–C) A summary of the membranolytic activity of
0 μM (control), 2.5 μM and 5 μM cecropin B on bacterial membrane-mimicking vesicles. Each horizontal line depicts the locally normalised inten-
sity of encapsulated HPTS in a single trapped vesicle, with global background subtraction, over time. The vesicle's membrane is considered intact
at high fluorescence intensity (red) and compromised at low fluorescent signal (blue). The intensity traces were ordered by the critical viability time
point, which is defined as the point when the fluorescence signal intensity of a vesicle decreases below 50% of its initial intensity. Total number of
analysed vesicles: NA = 433, NB = 419, NC = 407. D) Depicts the vesicle viability over time based on the administered concentration of cecropin B.
E) Event distribution of vesicle bursting and leakage as a function of drug concentration. F) Box plot depicting the time of bursting for the two
cecropin B concentrations investigated. At 0.001 significance level, the Welch's t-test revealed statistically significant differences in the means of
the two datasets.
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represents the transition between the high and low intensi-
ties and describes the rate of the leakage process. Based on
the rate of intensity decay, we can qualitatively infer whether
the vesicles are porated (slow leakage) or burst (instant loss
in intensity). However it is also possible that a certain num-
ber of intact but porated vesicles subsequently burst after dye
leakage. Fig. 4D–F combines the results from the separate
chambers to generate an overview describing the efficacy of
cecropin B on the bacterial membrane mimics.
The viability of the vesicles untreated with peptide was ob-
served to remain around 98% after 550 min. This confirms
the integrity of untreated vesicles over the span of the experi-
ment, and showcases the photostability of the encapsulated
dye. On the other hand, the viability of vesicles treated with
the higher 5 μM concentration of cecropin B deteriorated to
0% after 387.5 min of exposure while the lower 2.5 μM con-
centration led to a vesicle viability of 13% after 550 min. The
bursting events correspond to damage in the vesicle's inte-
grity either through leakage or complete vesicle lysis. In the
chambers with 2.5 μM, the mean time point for vesicle burst-
ing was 419.4 ± 3.4 min (N = 419, mean ± s.e.m.) while in the
case of 5 μM it was 218.3 ± 2.7 min (N = 407, mean ± s.e.m.).
Thus doubling the peptide concentration effectively halved
the vesicle bursting time, as expected for antimicrobial
agents that cooperatively assemble in bacterial membranes.31
Three repeats were conducted using the previous condi-
tions. The cumulative sum of the vesicles in the three repeats
for 0, 2.5 and 5 μM of cecropin B was 1042, 1103 and 1350 re-
spectively. The viability of the vesicles for the control after 550
min was 98 ± 0.3% while the mean time point (mean ± s.e.m.)
for vesicles bursting at 2.5 and 5 μM was 392.5 ± 2.8 min and
211.2 ± 2.2 min, respectively (independent repeats can be
found in ESI† Fig. S5 and S6).
4 Conclusions
We have designed a fully integrated microfluidic platform to
test the efficacy of AMPs on biomimetic vesicle membranes.
GUVs can be produced on demand, encapsulating a mem-
brane impermeable dye as an integrity marker. AMP activity is
quantified by studying the time taken for the vesicles to lyse
or porate, which is accompanied by dye leakage and a corre-
sponding decrease in vesicle fluorescence. The vesicles are
immobilised for long duration studies and can be controllably
washed and exposed to membrane active molecules. We vali-
dated this assay by studying the time-dependent activity of
the native antimicrobial peptide cecropin B on bacterial mim-
icking model membranes. This standardised platform can
now be used to quantify the activity of any AMPs, either
designed or native, that lyse or porate lipid membranes. Our
platform allows us to study over 1000 vesicles simultaneously
per experiment. The vesicles were continuously perfused with
a defined peptide concentration for the duration of the assay.
Cecropin B was found to disrupt negatively charged vesicle
membranes in a dose-dependent manner, consistent with the
cooperative assembly of AMPs in membranes typically accom-
panied with pore formation. The cecropin B concentrations
we tested are in the range of reported MIC values, thus prov-
ing that our assay yields data comparable to results from tra-
ditional biological assays.28,29 On the other hand, the
untreated vesicle population showed only a 2% loss in viabil-
ity throughout the experiment, ensuring the stability of the
vesicles in the trap chambers.
Our lab-on-a-chip platform can be utilised in a wide range
of biophysical applications and systematic studies that target
lipid membranes. The ability to controllably change the lipid
composition19 allows us to mimic bacterial or mammalian
cell membranes for studying the membranolytic and hemo-
lytic activities of novel peptides. We can thus use this device
to study both the efficacy and selectivity of antimicrobial pep-
tides in a quantitative, controlled manner as well as provide
mechanistic insights into their mode of action. The micro-
fluidic platform is tailored for drug development since it uses
minimal quantities of potentially expensive drug candidates
in comparison to bulk assays. Additionally, as demonstrated
with the parallel trap chambers, the assay can be further
parallelised to test multiple different drugs or drug concen-
trations in the same experiment. We envisage this assay as a
new biometrological standard for the pre-clinical develop-
ment of membrane-active polypeptide antimicrobials.
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